Tofacitinib in a Recalcitrant Case of Alopecia Areata
December 2022
in “
Zenodo (CERN European Organization for Nuclear Research)
”
Studysummary In this report, a 14-year-old female with stubborn alopecia areata was successfully treated with oral tofacitinib, indicating its potential effectiveness for severe cases.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
This article discusses a case of recalcitrant alopecia areata in a 14-year-old female who was successfully treated with oral tofacitinib. Alopecia areata is a non-cicatricial autoimmune disease characterized by smooth, round patches of hair loss. Tofacitinib is highlighted as a promising therapy for severe cases of alopecia areata, with increasing evidence supporting its efficacy. The case presented adds to the growing body of literature demonstrating the potential of tofacitinib in treating this condition.
